- Home
- GILD vs SPGI Comparison
GILD vs SPGI Comparison
Compare GILD & SPGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GILD | SPGI |
|---|---|---|
| Founded | 1987 | 1860 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.7B | 160.5B |
| IPO Year | 1992 | N/A |
Fundamental Metrics
Financial Performance| Metric | GILD | SPGI |
|---|---|---|
| Price | $124.40 | $537.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 13 |
| Target Price | $127.60 | ★ $609.31 |
| AVG Volume (30 Days) | ★ 6.5M | 1.5M |
| Earning Date | 02-10-2026 | 02-10-2026 |
| Dividend Yield | ★ 2.60% | 0.71% |
| EPS Growth | ★ 6514.05 | 21.42 |
| EPS | 6.42 | ★ 13.74 |
| Revenue | ★ $29,087,000,000.00 | $15,012,000,000.00 |
| Revenue This Year | $3.63 | $9.85 |
| Revenue Next Year | $3.10 | $7.32 |
| P/E Ratio | ★ $18.90 | $39.27 |
| Revenue Growth | 2.79 | ★ 9.04 |
| 52 Week Low | $88.57 | $427.14 |
| 52 Week High | $128.70 | $579.05 |
Technical Indicators
Market Signals| Indicator | GILD | SPGI |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 66.18 |
| Support Level | $116.88 | $511.31 |
| Resistance Level | $127.41 | $532.46 |
| Average True Range (ATR) | 2.46 | 9.14 |
| MACD | -0.16 | 1.67 |
| Stochastic Oscillator | 67.71 | 87.08 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About SPGI S&P Global Inc.
S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include commodity insights (Platts and other data), mobility (Carfax), and indexes.